Showing 481 - 500 results of 2,687 for search '"chemotherapy"', query time: 0.07s Refine Results
  1. 481
  2. 482
  3. 483
  4. 484
  5. 485
  6. 486
  7. 487
  8. 488
  9. 489
  10. 490

    The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases by Julio A. Ibarra

    Published 2012-01-01
    “…Historically, neoadjuvant chemotherapy has been used to treat patients with advanced breast disease in an attempt to convert them into candidates for breast conservation surgery. …”
    Get full text
    Article
  11. 491
  12. 492
  13. 493

    Neoadjuvant adebrelimab combined with chemotherapy (cisplatin/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS) by Yan Zhang, Qian Huang, Mengxia Li, Xi Zheng, Yanyang Liu, Long Tian, Guizhi Chen, Hongyu Xu, Daxing Zhu

    Published 2025-01-01
    “…To this end, we plan to conduct a study on adebrelimab in combination with chemotherapy for the neoadjuvant treatment of limited-stage SCLC.Methods and analysis This will be a single-arm, prospective study. …”
    Get full text
    Article
  14. 494

    MRI-based deep learning and radiomics for predicting the efficacy of PD-1 inhibitor combined with induction chemotherapy in advanced nasopharyngeal carcinoma: A prospective cohort study by Yiru Wang, Fuli Chen, Zhechen Ouyang, Siyi He, Xinling Qin, Xian Liang, Weimei Huang, Rensheng Wang, Kai Hu

    Published 2025-02-01
    “…Background: An increasing number of nasopharyngeal carcinoma (NPC) patients benefit from immunotherapy with chemotherapy as an induction treatment. Currently, there isn't a reliable method to assess the efficacy of this regimen, which hinders informed decision-making for follow-up care. …”
    Get full text
    Article
  15. 495

    When specific exercise is more effective than medication - Sensorimotor training is currently the most promising option to treat and prevent chemotherapy-induced peripheral neuropathy (CIPN). by Fiona Streckmann, Maryam Balke, Céline Hammadou, Bianca Schmidli, Oliver Faude, Sarah Koch

    Published 2025-01-01
    “… Introduction Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and clinically relevant adverse effect of chemotherapy, negatively impacting patient quality of life. …”
    Get full text
    Article
  16. 496

    Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years by Emiel A. M. Janssen, Håvard Søiland, Ivar Skaland, Einar Gudlaugson, Kjell H. Kjellevold, Arne Nysted, Jon-Arne Søreide, Jan P. A. Baak

    Published 2007-01-01
    “…Material and Methods: Prognostic comparison of Her2Neu, p110alpha (PIK3CA), Akt, mTOR, PTEN, MAI and cell-cycle regulators in 125 LNneg patients aged <55 years with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-based adjuvant systemic chemotherapy. Results: Twenty-one (17%) patients developed distant metastases = DMs (median follow-up: 134 months). p110alpha correlated (p = 0.01) with pAkt but only in PTEN-negatives; pAkt correlated (p = 0.02) with mTOR. …”
    Get full text
    Article
  17. 497

    Prevalence, intensity and risk factors of soil-transmitted helminthiasis after five effective rounds of preventive chemotherapy across three implementation units in Ondo State, Nigeria. by Hammed O Mogaji, Francisca O Olamiju, Fajana Oyinlola, Ijeoma Achu, Oladunni N Adekunle, Lydia E Udofia, Ekaette G Edelduok, Clement A Yaro, Olanike O Oladipupo, Alice Y Kehinde, Fatai Oyediran, Moses Aderogba, Louise K Makau-Barasa, Uwem F Ekpo

    Published 2025-01-01
    “…<h4>Background</h4>Routine epidemiological data are essential for monitoring the effectiveness of preventive chemotherapy (PC), optimizing resource allocation, and addressing the evolving needs in the elimination of soil-transmitted helminthiasis (STH). …”
    Get full text
    Article
  18. 498
  19. 499

    Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy by Cheng-Wei Huang, Ruo-Han Tseng

    Published 2024-01-01
    “…Herein, we report a patient with ovarian clear-cell carcinoma refractory to platinum-based chemotherapy, who was treated with a reduced dose of bevacizumab and pembrolizumab combination therapy and achieved a complete treatment response.…”
    Get full text
    Article
  20. 500